References
- RamachandranARamachandranSSnehalathaCIncreasing expenditure on health care incurred by diabetic subjects in a developing country: a study from IndiaDiabetes Care200730225225617259490
- NarayanKMBoyleJPGeissLSSaaddineJBThompsonTJImpact of recent increase in incidence on future diabetes burden: US, 2005–2050Diabetes Care20062992114211616936162
- BagustAHopkinsonPKMasloveLCurrieCJThe projected health care burden of type 2 diabetes in the UK from 2000 to 2060Diabet Med200219Suppl 41512121330
- CutlerDMEverettWThinking outside the pillbox – medication adherence as a priority for health care reformNew Engl J Med2010326171553155720375400
- CobdenDLeeWCBaluSJoshiAVPashosCLHealth outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitusPharmacotherapy200727794896217594200
- LeeWCBaluSCobdenDJoshiAVPashosCPrevalence and economic consequences of medication adherence in diabetes: a systematic literature reviewManag Care Interface2006197314116898343
- RozenfeldYHuntJSPlauschinatCWongKSOral antidiabetic medication adherence and glycemic control in managed careAm J Manag Care2008142717518269302
- CobdenDNiessenLWRuttenFFHBarrCERedekopWKRelationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetesValue Health201013113814719695005
- WatkinsJBMinshallMESullivanSDApplication of economic analyses in US managed care formulary decisions: a private payer’s experienceJ Manag Care Pharm200612972673517249905
- ValentineWJPalmerAJNicklassonLCobdenDRozeSImproving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targetsInt J Clin Pract20066091138114516939559
- NathanDMFinding new treatments for diabetes – how many, how fast … how good?New Engl J Med2007356543744017267901
- SonnenbergFABeckJRMarkov models in medical decision making: a practical guideMed Decis Making1993133223388246705
- FoneDHollinghurstSTempleMSystematic review of the use and value of computer simulation modelling in population health and health care deliveryJ Public Health Med200325432533514747592
- United Kingdom Prospective Diabetes Study GroupUnited Kingdom Prospective Diabetes Study 24: a 6-Year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapyAnn Intern Med19981281651759454524
- National Center for Health Statistics, Centers for Disease Control and PreventionNHANES 2007–2008 Dataset and Diabetes Fact Sheet Survey http://www.cdc.gov/nchs/fastats/diabetes.htm. Accessed Sep 22, 2009.
- DoddAHColbyMSBoyeKSFahlmanCKimSBriefelRRTreatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004Curr Med Res Opin20092571605161319469695
- 2009 Drug Red BookMontvale, NJMedical Economics Co.2009
- RodinHAHeatonAHWilsonARGarrettNAPlocherDWPlan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefitAm J Manag Care2009151288188820001169
- BriesacherBAAndradeSEFouayziHChanKAMedication adherence and use of generic drug therapiesAm J Manag Care200915745045619589012
- EvansJMDonnanPTMorrisADAdherence to oral hypoglycaemic agents prior to insulin therapy in type 2 diabetesDiabet Med200219868568812147151
- LawrenceDBRagucciKRLongLBParrisBSHelferLARelationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management programJ Manag Care Pharm200612646647116925454
- LunaBFeinglosMOral agents in the management of type 2 diabetes mellitusAm Fam Physician2001631747175611352285
- BraithwaiteRSMeltzerDOKingJTJrLeslieDRobertsMSWhat does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care200846434935618362813